

# M Hasib Sidiqi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7702637/m-hasib-sidiqi-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

417  
citations

13  
h-index

19  
g-index

68  
ext. papers

562  
ext. citations

4.3  
avg, IF

3.71  
L-index

#	Paper	IF	Citations
60	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1323-1329	2.2	68
59	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 30	7	29
58	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 497-502	7.1	27
57	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1020-1026	7.1	25
56	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 55	7	22
55	Daratumumab for the treatment of AL amyloidosis. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 295-301	1.9	20
54	Venetoclax for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 915-920	2.8	18
53	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , <b>2018</b> , 2, 3149-3154	7.8	17
52	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , <b>2018</b> , 2, 769-776	7.8	16
51	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1518-1523	7.1	15
50	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E141-E143	7.1	13
49	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 106	7	13
48	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2360-2364	4.7	13
47	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e108-e111	4.7	11
46	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1066-1071	7.1	9
45	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 1229-1234	6.6	8
44	The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. <i>Acta Haematologica</i> , <b>2020</b> , 143, 118-123	2.7	7

43	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1520-1525	4.7	6
42	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 4-9	7.1	6
41	Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 90	7	6
40	T-cell large granular lymphocytic leukemia and plasma cell disorders. <i>Haematologica</i> , <b>2019</b> , 104, e108-e110	6	6
39	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1131-1136	7.1	6
38	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1775-1779	4.4	5
37	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2132-2137	4.4	5
36	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 442-447	4.4	5
35	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E8-E10	7.1	5
34	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 52	7	4
33	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene CiloleuceL Therapy for Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 4106-4106	2.2	4
32	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2157-2159	4.7	3
31	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , <b>2019</b> , 3, 1226-1229	7.8	3
30	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1077-1081	4.4	3
29	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 446-454	7.1	3
28	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1402-1405	4.7	2
27	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3160-3160	2.2	2
26	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 928-935	4.4	2

25	Immune-mediated neuromuscular complications of graft-versus-host disease. <i>Muscle and Nerve</i> , <b>2021</b> , 63, 852-860	3.4	2
24	Joint Pain and Proteinuria. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1512-1513	27.4	1
23	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2019</b> , 134, 4560-4560	2.2	1
22	Therapy for relapsed multiple myeloma. <i>Panminerva Medica</i> , <b>2018</b> , 60, 174-184	2	1
21	A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS8055-TPS8055	2.2	1
20	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , <b>2020</b> , 136, 11-12	2.2	0
19	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , <b>2019</b> , 134, 3171-3171	2.2	0
18	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 63	7	0
17	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 274-277	4.4	0
16	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 59	7	0
15	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 62	7	0
14	Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 1380-1381	6.4	
13	Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	
12	Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 23-23	2.2	
11	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , <b>2021</b> , 105, 1615-1624	1.8	
10	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8023-8023	2.2	
9	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , <b>2018</b> , 132, 2147-2147	2.2	
8	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , <b>2018</b> , 132, 5610-5610	2.2	

- 7 Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. *Blood*, **2018**, 132, 3436-3436 2.2
- 6 T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. *Blood*, **2018**, 132, 5368-5368 2.2
- 5 Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. *Journal of Clinical Oncology*, **2019**, 37, 8011-8011 2.2
- 4 Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. *Blood*, **2019**, 134, 4505-4505 2.2
- 3 Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review. *Blood*, **2019**, 134, 5556-5556 2.2
- 2 Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. *Journal of Clinical Oncology*, **2020**, 38, 8516-8516 2.2
- 1 Imaging flow cytometry shows monosomy 17 in circulating plasma cells in myeloma.. *Pathology*, **2022**, 1.6